

Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism

Munro Peacock, John P. Bilezikian, Preston S. Klassen, Matthew D. Guo, Stewart A. Turner, and Dolores Shoback

Department of Medicine (M.P.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Medicine (J.P.B.), College of Physicians and Surgeons, Columbia University, New York, New York 10032; Amgen Inc. (P.S.K., M.D.G., S.A.T.), Thousand Oaks, California 91320; and Department of Veterans Affairs Medical Center (D.S.), Department of Medicine, University of California, San Francisco, California 94121

Calcimimetics increase the sensitivity of parathyroid calcium-sensing receptors to extracellular calcium, thereby reducing PTH secretion. This multicenter, randomized, double-blind, placebo-controlled study assessed the ability of the oral calcimimetic cinacalcet HCl to achieve long-term reductions in serum calcium and PTH concentrations in patients with primary hyperparathyroidism (HPT). Patients (n = 78) were randomized to cinacalcet or placebo. Cinacalcet was titrated from 30–50 mg twice daily during a 12-wk dose-titration phase. Efficacy was assessed during 12-wk maintenance and 28-wk follow-up phases. The primary endpoint was the achievement of normocalcemia [serum calcium \leq 10.3 mg/dl (2.57 mmol/liter)] with at least 0.5 mg/dl (0.12-mmol/liter) reduction from baseline. Plasma PTH, serum and urine bio-

chemistry, biochemical measures of bone turnover, bone mineral density, and safety were also assessed. Seventy-three percent of cinacalcet-treated patients vs. only 5% of placebo-treated patients achieved the primary endpoint ($P < 0.001$). Fasting predose plasma PTH decreased 7.6% in cinacalcet patients but increased 7.7% in placebo patients ($P < 0.01$). Bone mineral density was unchanged by cinacalcet, but bone resorption and formation markers increased ($P < 0.05$). Adverse events were mild and similar between treatment groups. Cinacalcet rapidly normalizes serum calcium and reduces PTH in patients with primary HPT, and these effects are maintained with long-term treatment. Cinacalcet may be an effective, nonsurgical approach for management of primary HPT. (*J Clin Endocrinol Metab* 90: 135–141, 2005)

PRIMARY HYPERPARATHYROIDISM (HPT) is a common disorder characterized by chronically elevated serum calcium and PTH concentrations. In the United States, many patients with primary HPT have mild, asymptomatic disease and do not meet the criteria for surgery (1). Patients with moderate to severe disease can experience worsening hypercalcemia, nephrolithiasis, loss of bone mineral density (BMD), neuromuscular weakness, and neurobehavioral symptoms including easy fatigability and impaired cognitive function (2). Parathyroidectomy is usually curative, but there are few nonsurgical treatment alternatives for patients who fail surgery, have contraindications to surgery, do not wish to have surgery, or do not meet current guidelines for surgery. Thus, there is a need for therapeutic agents that directly reduce serum calcium and PTH concentrations in patients with primary HPT.

The calcium-sensing receptor (CaR) located on cells of the parathyroid gland is the principal regulator of PTH secretion (3). Type II calcimimetics are a novel class of compounds that directly reduce PTH levels by binding to the CaR and increasing its sensitivity to extracellular calcium (4, 5). Cina-

calcet HCl, hereafter referred to as cinacalcet, is a calcimimetic that has been shown to lower plasma PTH, serum calcium, and serum phosphorus in patients with secondary HPT (6, 7). In an earlier study, we showed that cinacalcet also had efficacy in the short-term reduction of serum calcium and PTH concentrations in patients with primary HPT (8). We conducted this 52-wk, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy and safety of cinacalcet in reducing serum calcium and PTH levels in patients with mild to moderate primary HPT. In addition, the impact of cinacalcet on bone turnover and BMD was assessed.

Patients and Methods

Patients

The study was conducted at 18 centers in the United States. Seventy-eight adult patients, 21 men and 57 women, aged 27–83 yr, with primary HPT were enrolled in the study over 14 wk between 1999 and 2000. Eligibility requirements included serum calcium concentration greater than 10.3 mg/dl (2.57 mmol/liter) and less than 12.5 mg/dl (3.12 mmol/liter) and plasma PTH concentration greater than 45 pg/ml (4.73 pmol/liter). PTH was measured on at least two occasions at least 7 d apart during the 12-month period before baseline. Exclusion criteria included pregnancy, creatinine clearance less than 50 ml/min (0.83 ml/sec) (9), treatment with bisphosphonates or fluoride in the 90 d before baseline, familial hypocalciuric hypercalcemia, or fasting urine calcium/creatinine in milligrams (molar) ratio less than 0.05 (0.14). Because cinacalcet inhibits cytochrome P450 2D6 (CYP2D6), patients were excluded if they required drugs that are metabolized by this enzyme and have a narrow therapeutic index, such as flecainide, thioridazine, and many tricyclic

First Published Online November 2, 2004

Abbreviations: BALP, Bone-specific alkaline phosphatase; BMD, bone mineral density; CaR, calcium-sensing receptor; DPD, deoxypyridinoline; HPT, hyperparathyroidism; NTx, N-telopeptide.

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

antidepressants. Women on stable doses of selective estrogen receptor modulators or estrogen replacement therapy were eligible. The Institutional Review Board at each center approved the study, and written informed consent was obtained from all patients.

Study design

This was a multicenter, randomized, double-blind, placebo-controlled study. Patients were randomized in a 1:1 ratio to receive either cinacalcet or placebo after a 30-d screening period. The study included a 12-wk dose-titration phase, a 12-wk maintenance phase during which the primary efficacy endpoint was measured, and a 28-wk follow-up phase to gather additional safety and efficacy information. Patients initially received 30 mg cinacalcet or placebo twice daily. The dose was increased sequentially to 40 and 50 mg twice daily at study wk 4 and 8 if patients were still hypercalcemic (serum calcium > 10.3 mg/dl). Patient visits occurred weekly during the titration phase (wk 1–12) and monthly during the maintenance (wk 13–24) and follow-up (wk 25–52) phases. Pharmacodynamic data were collected at wk 3, 12, and 24 after the morning dose of study drug to assess effects of study drug on serum calcium and PTH concentrations over 8 h.

The primary endpoint was the proportion of patients achieving a mean serum calcium less than or equal to 10.3 mg/dl (2.57 mmol/liter) and a reduction from baseline of at least 0.5 mg/dl (0.12 mmol/liter) during the maintenance phase. Secondary endpoints included changes from baseline in serum and urine biochemistries and BMD. Adverse events were recorded throughout the study.

Measurements

Blood samples were collected for measurement of serum calcium and PTH at each study visit after an overnight fast and before the morning dose of study drug. Samples for serum calcium and PTH were also collected at 2, 4, and 8 h after the morning dose of study drug at wk 3, 12, and 24 for pharmacodynamic analysis. Serum calcium [coefficient of variation (CV) = 1.4–1.5%] was measured by standard methods. Intact PTH (CV = 4.2–6.4%) was measured using a double-antibody immunoradiometric assay (Allegro PTH, Nichols Institute Diagnostics, San Juan Capistrano, CA).

Serum phosphorus (CV = 2.2–2.4%), creatinine (CV = 1.6–13.5%), 1,25-dihydroxyvitamin D (CV = 9.1–20.3%), bone-specific alkaline phosphatase (BALP) (CV = 9.9–11.4%), and N-telopeptide (NTx) (CV = 6.4–9.5%) were measured at baseline and at wk 24 and 52. Serum 1,25-dihydroxyvitamin D was measured by radioreceptor assay (Endocrine Sciences, Calabasas Hills, CA). Serum NTx levels were determined by ELISA (Osteomark NTx assay, Ostex International, Seattle, WA). Urine was collected over 24 h and after an overnight fast at baseline and at wk 24 and 52 for the measurement of calcium (CV = 3.4–4.9%), phosphorus (CV = 1.7–1.9%), NTx (CV = 5.1–11.3%), and deoxypyridinoline (DPD) (CV = 8.6–17.1%), which were expressed as a ratio with urine creatinine. Urine calcium, phosphorus, creatinine, and urine-free DPD were measured by Covance Central Laboratories (Indianapolis, IN). Tubular reabsorption of calcium ($TmCa = [\text{total plasma calcium} \times 0.59 - \text{urine calcium} \times \text{plasma creatinine} / \text{urine calcium}] / 1 - 0.08 \log_e [\text{total plasma calcium} \times 0.59 / \{\text{urine calcium} \times \text{plasma creatinine} / \text{urine calcium}\}]$) and tubular reabsorption of phosphorus ($TmP = [\text{plasma phosphate} - \text{urine phosphate} \times \text{plasma creatinine} / \text{urine phosphate}] / 1 - 0.1 \log_e [\text{plasma phosphate} / \{\text{urine phosphate} \times \text{plasma creatinine} / \text{urine phosphate}\}]$) were calculated from the calcium and phosphate (in milligrams) values in the respective fasting blood and urine samples using the indicated formulas (10).

BMD of the lumbar spine, total femur, and 1/3 distal radius was measured either by dual-energy x-ray absorptiometry at baseline and at wk 24 and 52 using a Hologic densitometer (Hologic, Waltham, MA) ($n = 27$, cinacalcet; $n = 26$, placebo) or a Lunar densitometer (Lunar Inc., Madison, WI) ($n = 13$, cinacalcet; $n = 12$, placebo). For each patient, BMD was measured on the same densitometer throughout the study. To combine measurements in men and women over a wide age range made on either Hologic or Lunar machines, BMD was expressed as a Z score. To examine for longitudinal changes, the changes in Z score for each individual were calculated, and the mean changes for the placebo and cinacalcet groups were presented as mean change in Z score.

Statistical analysis

The proportion of patients achieving a serum calcium less than or equal to 10.3 mg/dl (2.57 mmol/liter) and a reduction in serum calcium of at least 0.5 mg/dl (0.12 mmol/liter) from baseline was determined using mean values for each patient derived from up to three measurements obtained during the maintenance phase. The difference in the proportion of patients achieving the primary endpoint in the cinacalcet and placebo groups was determined using logistic regression and included all randomized patients. For this analysis, patients leaving the study before the maintenance phase were considered not to have achieved the primary endpoint, regardless of serum calcium values at the time of withdrawal. An additional analysis was performed using the last on-study serum calcium value for patients who withdrew before the maintenance phase. Biochemical and BMD variables were compared between placebo and cinacalcet groups at wk 24 and 52 using one-way ANOVA. Adverse events were tabulated by treatment group and analyzed using descriptive statistics.

Results

A total of 78 patients with primary HPT were randomized (40 cinacalcet, 38 placebo). One patient who was randomized to placebo withdrew before receiving the study drug. The mean age was 62 yr in both groups (range, 27–83 yr), and the majority of patients were women (70% cinacalcet, 76% placebo). Nine patients in each group had a prior history of parathyroidectomy. Twenty-eight of 40 patients (70%) in the cinacalcet group and 28 of 38 patients (74%) in the placebo group completed the 52-wk study.

Mean baseline biochemical values were similar between treatment groups and characteristic of patients with mild to moderate primary HPT (Table 1). In the cinacalcet group, the mean baseline serum calcium level was 10.7 ± 0.5 mg/dl (2.67 ± 0.12 mmol/liter), and the mean PTH level was 105 ± 36 pg/ml (11.0 ± 3.78 pmol/liter) compared with 10.7 ± 0.4 mg/dl (2.67 ± 0.10 mmol/liter) and 120 ± 54 pg/ml (12.6 ± 5.68 pmol/liter), respectively, in placebo-treated patients.

Mean (sd) baseline Z scores for cinacalcet were 0.15 (2.20) at the lumbar spine, -0.31 (0.91) at the total femur, and -0.46 (1.41) at the 1/3 distal radius. For placebo patients, the baseline Z scores were -0.10 (2.27) at the lumbar spine, -0.33 (0.96) at the total femur, and -0.31 (1.38) at the 1/3 distal radius. Mean (sd) baseline T scores for the cinacalcet group were -0.90 (1.55) at the lumbar spine, -1.20 (1.02) at the total femur, and -1.61 (1.58) at the 1/3 distal radius. For placebo patients, the baseline T scores were -1.22 (1.57) at the lumbar spine, -1.32 (1.07) at the total femur, and -1.79 (1.62) at the 1/3 distal radius.

During the maintenance phase, 73% of patients in the cinacalcet group achieved the primary endpoint [predose serum calcium ≤ 10.3 mg/dl (2.57 mmol/liter) and a decrease from baseline of ≥ 0.5 mg/dl (0.12 mmol/liter)] compared with 5% of the placebo group ($P < 0.001$). When serum calcium values from patients who withdrew during the dose-titration phase were included in the analysis, 88% of the cinacalcet group achieved the primary endpoint, compared with 5% of the placebo group ($P < 0.001$). Mean serum calcium levels were reduced to the normal range within the first 2 wk of treatment with cinacalcet (Fig. 1) and remained normal throughout the 52 wk of the study. In the placebo group, the mean serum calcium levels did not change significantly from baseline levels throughout the study.

Corresponding modest but significant reductions in fast-

TABLE 1. Biochemistry (mean ± SD [range]) at baseline and wk 24 and 52

Parameter	Placebo			Cinacalcet			Reference range
	Baseline, n = 38	wk 24, n = 28	wk 52, n = 28	Baseline, n = 40	wk 24, n = 31	wk 52, n = 27	
Serum calcium (mg/dl)	10.7 ± 0.4 (10.2–11.9)	10.7 ± 0.8 (9.5–12.3)	10.9 ± 0.7 (9.4–12.2)	10.7 ± 0.5 (9.7–12.5)	9.3 ± 0.5 (8.3–10.6)	9.7 ± 0.5 ^a (8.6–10.8)	8.5–10.5
Plasma PTH (pg/ml)	120 ± 54 (46–320)	120 ± 56 (38–325)	112 ± 49 (35–263)	105 ± 36 (41–224)	84 ± 34 (37–191)	91 ± 34 (37–201)	10–65
Serum phosphorus (mg/dl)	2.8 ± 0.4 (2.0–3.7)	2.8 ± 0.5 (1.7–3.9)	2.7 ± 0.4 (2.0–3.7)	2.7 ± 0.5 (1.9–3.7)	3.3 ± 0.6 (2.2–4.5)	3.2 ± 0.5 ^a (2.3–4.0)	2.2–5.1
24-h urine Ca/Cr mg ratio	0.27 ± 0.10 (0.09–0.54)	0.26 ± 0.11 (0.11–0.51)	0.29 ± 0.12 (0.09–0.50)	0.31 ± 0.13 (0.07–0.59)	0.27 ± 0.12 (0.06–0.59)	0.27 ± 0.12 (0.08–0.50)	0.07–0.29
Fasting urine Ca/Cr mg ratio	0.22 ± 0.10 (0.10–0.59)	0.21 ± 0.10 (0.11–0.56)	0.25 ± 0.12 (0.10–0.57)	0.26 ± 0.14 (0.10–0.64)	0.20 ± 0.11 (0.10–0.48)	0.16 ± 0.07 ^a (0.10–0.35)	0.02–0.22
Serum 1,25 D (pg/ml)	82 ± 32 (30–174)	68 ± 20 (32–107)	80 ± 23 (37–129)	81 ± 29 (31–169)	69 ± 19 (42–119)	79 ± 24 (46–129)	18–62
Serum BALP (ng/ml)	20.4 ± 12.2 (6.7–61.0)	17.7 ± 9.0 (5.7–39.0)	21.3 ± 15.9 (6.8–88.0)	18.7 ± 7.3 (6.0–31.0)	23.2 ± 10.5 (8.6–52.0)	25.3 ± 11.1 ^b (8.1–48.0)	7.3–22.4
Serum NTx (nm)	21 ± 10 (9–47)	22 ± 10 (11–54)	21 ± 11 (9–48)	18 ± 6 (9–41)	24 ± 10 (12–68)	23 ± 9 ^b (10–60)	5.4–24.2
Urine NTx/Cr (nmol/mmol)	64 ± 53 (15–213)	59 ± 49 (12–197)	61 ± 40 (13–135)	48 ± 22 (11–96)	72 ± 35 (25–158)	77 ± 55 ^b (22–297)	17–188
Urine DPD/Cr (nmol/mmol)	9.1 ± 4.4 (2.8–20.0)	9.3 ± 4.2 (2.7–18.0)	9.7 ± 5.1 (3.6–28.0)	8.9 ± 4.1 (3.8–21.0)	10.9 ± 4.6 (4.3–23.0)	11.0 ± 4.8 (3.9–25.0)	3.0–7.4
TmCa (mg/100 ml GF)	8.8 ± 0.7 (7.5–10.5)	8.8 ± 0.8 (6.9–10.9)	8.8 ± 0.6 (7.7–9.7)	8.8 ± 0.7 (7.4–10.5)	7.8 ± 0.9 (6.1–9.9)	8.3 ± 0.9 ^c (6.7–10.6)	6.6–10.5
TmP (mg/100 ml GF)	2.7 ± 1.1 (0.38–5.6)	2.8 ± 1.0 (0.72–4.5)	2.7 ± 0.8 (1.1–4.5)	2.7 ± 0.8 (0.73–4.5)	3.7 ± 1.0 (1.97–6.5)	3.5 ± 1.0 ^c (2.1–5.7)	2.5–5.4

^a P < 0.001 for cinacalcet value at wk 52 compared with placebo value at wk 52.
^b P < 0.05 for cinacalcet value at wk 52 compared with placebo value at wk 52.
^c P < 0.001 for wk 52 value compared with baseline.

ing plasma PTH (measured ~12 h after administration of study drug) were observed in the cinacalcet group. Mean plasma predose PTH decreased by 7.6% from 105 ± 36 pg/ml (11.0 ± 3.78 pmol/liter) to 95 ± 34 pg/ml (10.0 ± 3.55 pmol/liter) during the maintenance phase compared with a 7.7% increase from 120 ± 54 to 127 ± 53 pg/ml (12.6 ± 5.69 to 13.3 ± 5.52 pmol/liter) in the placebo group (P < 0.01; Fig. 2). In the cinacalcet group, predose plasma PTH reductions were maintained throughout the follow-up period.


Pharmacodynamic data collected at wk 24 demonstrated that the serum calcium concentrations remained unchanged after the morning dose of cinacalcet, whereas the corresponding plasma PTH concentrations underwent cyclic changes with dosing. At wk 24, mean serum calcium was normal, whereas mean plasma PTH remained elevated at the predose measurement. After the morning dose of cinacalcet, serum calcium was unchanged at all time points measured (Fig. 3A), whereas PTH decreased by 37% into the normal range at 2 h after dose (P < 0.0001) and gradually returned toward predose levels by 8 h (Fig. 3B). In the placebo group, no changes in calcium or PTH concentrations were observed over the corresponding time period. Results were similar at wk 3 and 12 (data not shown), indicating that no changes in serum calcium occurred once steady state had been achieved, but plasma PTH continued to undergo pharmacodynamic changes with dosing.

Mean fasting predose biochemistries at baseline and at wk 24 and 52 are shown in Table 1. Serum phosphorus increased in the cinacalcet group and at wk 52 was higher (P < 0.001) than in the placebo group. The fasting urine calcium-creatinine ratio and the 24-h urine calcium-creatinine ratio decreased in the cinacalcet group, although the difference between treatment groups was statistically significant only for the fasting calcium-creatinine ratio (P < 0.001). At wk 52, tubular reabsorption of calcium decreased (P < 0.001) and phosphorus reabsorption increased (P < 0.001) from baseline in the cinacalcet group, whereas there were no changes in the placebo group. Serum 1,25-dihydroxyvitamin D concentrations were similar in both groups at wk 52 and unchanged from baseline. Serum creatinine and 24-h urine creatinine remained relatively constant and similar in both groups throughout the study.

Some markers of bone turnover—serum BALP, serum NTx, and the urine NTx-creatinine ratio—were increased (P < 0.05) at wk 52 in the cinacalcet group compared with placebo, but remained in the normal range. The urine DPD-creatinine ratio increased in the cinacalcet group, but at wk 52, it was not significantly higher than in the placebo group. In the placebo group, there was no significant change in any of the biochemical markers of bone turnover during the study.

BMD was measured at baseline and at wk 24 and 52 and expressed as a Z score. In general, few differences in mean change in Z score occurred between the cinacalcet and placebo groups after 24 or 52 wk of treatment. At wk 24, the mean change in Z score at the lumbar spine was significantly lower in the cinacalcet group compared with the placebo group (P < 0.05) (Table 2); however, no difference between groups was observed at wk 52. No other significant differences for the lumbar spine, total femur, or 1/3 distal radius

FIG. 1. Comparison of predose serum calcium concentrations in patients receiving cinacalcet or placebo. The normal serum calcium concentration range (8.4–10.3 mg/dl) is indicated by the shaded area. Patients receiving cinacalcet experienced a significant reduction in serum calcium compared with patients administered placebo ($P < 0.001$). BL, Baseline value. Data are presented as mean \pm SE.




at wk 24 or 52 were observed between treatment groups (Table 2).

Nine patients in each treatment group (23% of the study population) had previously undergone unsuccessful parathyroidectomy. Seven of these patients in the cinacalcet group normalized their serum calcium and achieved the primary outcome, compared with one patient in the placebo group. In the cinacalcet group, mean serum calcium decreased from 10.8 mg/dl (2.70 mmol/liter) at baseline to 9.5 mg/dl (2.38 mmol/liter) at wk 52. In placebo-treated patients who had previous parathyroidectomy, serum calcium remained at baseline levels [11.1 mg/dl (2.78 mmol/liter)] throughout the study. PTH levels decreased by 10.5% in cinacalcet-treated patients with a previous parathyroidectomy and increased 3.1% in placebo-treated patients with previous parathyroidectomy. When BMD data were ana-

lyzed separately for these patients, the data were not different from the treatment groups as a whole (data not shown).

Cinacalcet was well tolerated in this study, and occurrence of adverse events was similar between treatment groups. The two most common adverse events were nausea (28% cinacalcet, 16% placebo) and headache (23% cinacalcet, 41% placebo). Similar numbers of patients in each group withdrew from the study because of adverse events (eight cinacalcet, six placebo). Three of these patients from the cinacalcet group experienced serum calcium levels less than 8.0 mg/dl (2.00 mmol/liter) while receiving the lowest dose of study drug and, in accordance with the study protocol, were withdrawn from the study. Two cinacalcet-treated patients experienced mild paresthesias that were considered treatment related. Serum calcium values were 7.9 mg/dl (1.98 mmol/liter) in the three patients who withdrew because of asymptomatic

FIG. 2. Comparison of percent change of predose plasma PTH concentrations in patients receiving cinacalcet or placebo. Patients receiving cinacalcet experienced a 7.6% reduction in plasma PTH compared with a 7.7% increase in the placebo group ($P < 0.01$) during the maintenance phase. BL, Baseline value. Data are presented as mean \pm SE.






FIG. 3. Response to cinacalcet or placebo before (0), and at 2, 4, and 8 h after the morning dose for serum calcium (A) and plasma PTH (B). Data were collected at wk 24. The normal ranges for serum calcium (8.4–10.3 mg/dl) and plasma PTH (10–65 pg/ml) are indicated by the shaded areas. BL, Baseline value. Data are presented as mean ± SE.

hypocalcemia and 7.8 mg/dl (1.95 mmol/liter) and 8.1 mg/dl (2.02 mmol/liter) in the patients who experienced paresthesias.

Discussion

In this study, cinacalcet administered twice daily rapidly normalized predose serum calcium in the majority of patients and caused modest reductions in predose PTH concentrations in patients with mild to moderate primary HPT. The effect of cinacalcet was sustained over 52 wk with no evidence of fluctuations in serum calcium concentration after individual doses once steady state had been established. These results confirm and extend the findings of our previ-

TABLE 2. Mean change in Z score from baseline at wk 24 and 52

	wk 24	wk 52
Lumbar spine		
Cinacalcet	-0.08 (0.20) ^a	0.00 (0.21)
Placebo	0.05 (0.23)	0.03 (0.29)
Total femur		
Cinacalcet	-0.03 (0.28)	-0.01 (0.22)
Placebo	0.03 (0.16)	-0.02 (0.18)
Distal radius (1/3)		
Cinacalcet	0.01 (0.17)	-0.05 (0.32)
Placebo	0.02 (0.24)	-0.01 (0.36)

Values are mean (SD).

^a P = 0.023 for change in cinacalcet compared with change in placebo.

ous short-term study (15 d plus a 7-d follow-up) that showed cinacalcet is effective in reducing serum calcium in patients with primary HPT (8). During the maintenance phase, 73% of cinacalcet-treated patients achieved normocalcemia with a decrease of at least 0.5 mg/ml (0.12 mmol/liter) from baseline, whereas only 5% of placebo-treated patients achieved this target. The proportion increased to 88% in the cinacalcet group compared with 5% in the placebo group when serum calcium values for patients who withdrew before the maintenance phase were included. In 90% of patients, the lowest dose of cinacalcet, 30 mg twice daily, was sufficient to induce normocalcemia, and no patients required titration to the maximum permitted dose of 50 mg twice daily.

During the maintenance phase, predose plasma PTH concentrations were reduced by approximately 8% with cinacalcet treatment. It should be noted that this value, which reflects hormone concentration before the morning dose of cinacalcet, underestimates PTH reduction over 24 h. At wk 24, pharmacodynamic data demonstrated that plasma PTH concentration 2 h after dosing decreased into the normal range (Fig. 3B), corresponding to a 60% reduction from baseline. Assuming that the decrease in PTH after the evening dose was similar to that after the morning dose, the area under the curve indicates that there was an approximately 20% reduction in plasma PTH over each 24-h cycle. Furthermore, there was no indication from the pharmacodynamic data that this response changed with length of time on drug. In contrast to the cyclic change seen in PTH, serum calcium remained unchanged over the 8-h sampling period after the morning dose of cinacalcet. These serum calcium results indicate that once steady state has been achieved, no sharp declines in serum calcium occur after individual doses; thus the risk of acute hypocalcemia and accompanying symptoms appears to be avoided with twice-daily dosing with cinacalcet in patients with primary HPT.

Drugs to manage the hypercalcemia of primary HPT, such as estrogens, selective estrogen receptor modulators, and bisphosphonates, have shown a limited ability to treat the disorder (11–14). These agents act primarily by inhibiting bone resorption, although their effects on serum calcium are relatively small. Cinacalcet treatment was highly effective in reducing serum calcium levels in this study, and suppression was maintained during 1 yr of treatment, suggesting that cinacalcet may be an important therapeutic agent for managing primary HPT, particularly when parathyroidectomy is not a viable option. Indeed, nine patients in each group (23% of the study population) had previously undergone unsuccessful parathyroidectomy. Seven of these patients in the cinacalcet group normalized their serum calcium and achieved the primary outcome, compared with one patient in the placebo group. Although this study did not include patients with severe primary HPT or parathyroid carcinoma, our preliminary reports indicate that cinacalcet may also successfully reduce serum calcium in these patients (15, 16).

In addition to normalizing serum calcium, cinacalcet treatment increased serum phosphorus. By wk 12, serum phosphorus levels and tubular reabsorption of phosphorus had increased, and the fasting urine calcium-creatinine ratio and tubular reabsorption of calcium had decreased in the cina-

calcet group, probably reflecting the renal effect of the overall decrease in plasma PTH over a 24-h cycle of dosing. The observation that serum calcium and tubular reabsorption of calcium were normal while predose PTH levels remained elevated suggests that cinacalcet, in addition to its effects on PTH secretion, also alters the relationship between PTH and its action on tubular calcium reabsorption. In kidney, this could be through a shift in the dose-response curve of PTH on tubular calcium reabsorption and/or by a direct effect of cinacalcet on the CaR in the renal tubule. The decrease in fasting urine calcium excretion was not accompanied by a corresponding significant decrease in 24-h calcium excretion. Because 24-h urine calcium has a component from intestinal absorption of calcium, this lack of decrease is consistent with the finding that the predose serum 1,25-dihydroxyvitamin D levels were not altered by cinacalcet.

Bone turnover may be increased in primary HPT. In our HPT patients, the biochemical markers of bone turnover for the group were in the normal range at baseline, reflecting the relative mildness of the disease. After treatment, some bone turnover markers significantly increased in the cinacalcet group, although the mean value remained in the normal range. The increase in bone turnover markers is of interest because it occurred in conjunction with an overall decrease of approximately 20% in plasma PTH levels. A possible explanation is the effect of daily fluctuating plasma PTH levels on bone turnover induced by the twice-daily dosing of cinacalcet, because it is known that daily injected PTH (1–34) has a stimulatory effect on bone turnover (17). A direct effect of cinacalcet on bone turnover cannot be excluded, however, and additional studies will be needed in this area.

In our patients, spine BMD was normal, but hip and forearm BMDs were in the osteopenic range, as expected in patients with this degree of primary hyperparathyroidism. Over the 52 wk of the study, no clinically significant differences in change in BMD were observed between the cinacalcet and placebo groups.

Cinacalcet was well tolerated in this study. Occurrences of adverse events and treatment-related adverse events were similar between the placebo and cinacalcet groups. Adverse events reported during the study were generally mild or moderate and resulted in only a small number of withdrawals.

The comparative utility and cost-benefit between cinacalcet and parathyroidectomy as treatment modalities for primary HPT have yet to be established. Although parathyroidectomy is usually curative and reverses abnormal biochemistry and symptoms, there is a pressing need for medical therapy to normalize serum calcium in patients who have either a contraindication to or have failed parathyroidectomy. Disease severity in this study ranged from symptomatic, with 18 of the 79 patients having previously had a failed parathyroidectomy, to asymptomatic. In patients who had symptoms, had a failed parathyroidectomy, or who were apparently asymptomatic, cinacalcet was equally effective in normalizing serum calcium. Although mild primary HPT with no apparent symptoms is currently managed by regular medical follow-up, *i.e.* watchful waiting, the long-term effects of mild hyperparathyroidism (18, 19) and hypercalcemia (20) on increasing premature cardiovascular death is of concern. Whether therapy should be considered for other-

wise asymptomatic mild hypercalcemia, and what the choice of such therapy should be, require additional study before a change from the current management of watchful waiting can be recommended.

In conclusion, in these patients with primary HPT, cinacalcet was highly effective in normalizing serum calcium levels and reducing PTH, and this effect was maintained over long-term administration. The drug was well tolerated and may provide a valuable and effective management option for patients with primary HPT.

Acknowledgments

Received May 7, 2004. Accepted October 25, 2004.

Address all correspondence and requests for reprints to: Munro Peacock, M.D., Director, General Clinical Research Center, University Hospital, 550 University Boulevard, UH5595, Indianapolis, Indiana 46202. E-mail: mpeacock@iupui.edu.

This study was sponsored by Amgen Inc.

The following primary investigators also participated in the 990120 Study: M. Block (Phoenix, AZ), M. Bolognese (Bethesda, MD), B. Esayag-Tendler (Farmington, CT), A. Firek (Loma Linda, CT), W. Greth (West Reading, PA), H. Katzeff (New Hyde Park, NY), M. Kipnes (San Antonio, TX), R. Lang (Hamden, CT), R. Levy (Olympia, WA), R. Marcus (Palo Alto, CA), R. Rude (Los Angeles, CA), S. Scumpia (Austin, TX), S. Silverman (Beverly Hills, CA), F. Singer (Santa Monica, CA), R. Smallridge (Jacksonville, FL), J. Tucci (Providence, RI), and S. Wallach (New York, NY).

References

1. Bilezikian JP, Potts Jr JT, Fuleihan G-H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA 2002 Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. *J Bone Miner Res* 17:N2–N11
2. Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH 1995 Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. *Ann Surg* 222:402–412
3. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC 1993 Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. *Nature* 366:575–580
4. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF 1998 Calcimimetics with potent and selective activity on the parathyroid calcium receptor. *Proc Natl Acad Sci USA* 95:4040–4045
5. Nemeth EF, Fox J 1999 Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. *Trends Endocrinol Metab* 10:66–71
6. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ 2003 The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. *Kidney Int* 63:248–254
7. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA 2003 The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. *J Am Soc Nephrol* 14:575–583
8. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M 2003 The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. *J Clin Endocrinol Metab* 88:5644–5649
9. Cockcroft DW, Gault MH 1976 Prediction of creatinine clearance from serum creatinine. *Nephron* 16:31–41
10. Peacock M 2002 Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. *J Bone Miner Res* 17:N87–N94
11. Selby PL, Peacock M 1996 Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. *N Engl J Med* 314:1481–1485
12. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ 2003 Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. *J Clin Endocrinol Metab* 88:1174–1178
13. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR 1993 Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. *J Clin Endocrinol Metab* 77:1067–1071
14. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, Lo KW, Cockram

- CS 2003 Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. *J Clin Endocrinol Metab* 88:581–587
15. Peacock M 2002 Normalization of hypercalcemia with calcimimetic AMG 073 in a patient with metastatic parathyroid cancer. *J Bone Miner Res* 17:S381
 16. Silverberg SJ, Faiman JP, Bilezikian JP, Shoback DM, Rubin MR, McCary LC, Olson KA, Turner SA, Peacock M 2003 The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary hyperparathyroidism after parathyroidectomy. *J Bone Miner Res* 18:S171
 17. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 334:1434–1441
 18. Lundgren E, Lind L, Palmer M, Jakobsson S, Ljunghall S, Rastad J 2001 Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. *Surgery* 130:978–985
 19. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekblom A 2002 Clinical presentation of primary hyperparathyroidism in Europe—nationwide cohort analysis on mortality from nonmalignant causes. *J Bone Miner Res* 17(Suppl 2):N68–N74
 20. Leifsson BG, Ahren B 1996 Serum calcium and survival in a large health screening program. *J Clin Endocrinol Metab* 81:2149–2153

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.